Use of μ1-opioid receptor agonist tafalgin in integrative therapy of chronic pain syndrome in progressive multiple myeloma. Clinical observation

Chronic pain syndrome developing in patients with oncological diseases significantly decreases their quality of life which makes effective integrative analgetic therapy a pressing issue. Currently, drugs various pharmaceutical groups are used for management and administered subsequentially accordance the intensity visual analogue scale. For moderate severe syndrome, opioid analgesics have side effects limiting use some cases. Trials showed that new highly specific μ1-opioid receptor agonist tafalgin is characterized by high bioavailability, fast absorption, biotransformation, absence accumulation its safety profile favorable. Pronounced analgesic effect tafalgin, as well ease administration significant adverse events, allow to improve chronic syndrome.